Pregledni rad
Potential of matrix metalloproteinases and their inhibitors in colorectal carcinoma patients
LJiljana Mayer
; Department of Clinical Chemistry, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mihaela Gaće
; Department of Clinical Chemistry, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sanja Dobrijević
; Department of Clinical Chemistry, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Zvjezdana Špacir-Prskalo
; Department of Clinical Chemistry, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sažetak
Colorectal carcinoma (CRC) is the third most common type of cancer worldwide. Early stages of colorectal cancer are associated with good survival rates. However, most colorectal cancers are diagnosed at advanced stages when disease is no longer limited to bowel wall. Penetration through the bowel wall is partly attributed to disfunctionate extracellular matrix (ECM) remodeling.
Matrix metalloproteinases (MMPs) are enzymes that have an important role in ECM degradation. Activity of MMPs is controlled by tissue inhibitors of metalloproteinases or TIMPs. MMP-1, -2, -3. -7, -9, -13 blood levels correlate with the stage of disease. In fact, determining the concentrations of MMPs and TIMPs in plasma/serum may differentiate colorectal adenomas from colorectal carcinomas. Furthermore, a correlation between the anastomotic leakage in colorectal cancer surgery and levels of TIMP-1, MMP-8 and MMP-9 has been found. TIMP-1 was also considered in monitoring chemotherapy effects.
In this paper we review current applications of quantifying MMPs and TIMPs and their implications for clinical practice.
Ključne riječi
extracellular matrix; matrix metalloproteinase; tissue inhibitors of metalloproteinases; colorectal carcinoma
Hrčak ID:
276074
URI
Datum izdavanja:
25.11.2012.
Posjeta: 484 *